Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Pre-Study Kickoff Meeting Conduct – V 2.0

Posted on By

BA-BE Studies: SOP for Pre-Study Kickoff Meeting Conduct – V 2.0

Standard Operating Procedure for Pre-Study Kickoff Meeting Conduct in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/034/2025
Supersedes SOP/BA-BE/034/2022
Page No. Page 1 of 12
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for conducting a pre-study kickoff meeting for Bioavailability/Bioequivalence (BA/BE) studies to ensure that all relevant stakeholders are aligned on study objectives, timelines, roles, and responsibilities prior to study initiation.

2. Scope

This SOP applies to all BA/BE studies coordinated or sponsored by the organization and involves all departments and stakeholders participating in study execution including Clinical, QA, Regulatory, Medical, Data Management, Pharmacovigilance, and CROs (if applicable).

3. Responsibilities

  • Clinical Project Manager: Responsible for organizing and leading the pre-study kickoff meeting.
  • Functional Department Heads: Present functional area responsibilities and confirm resource availability.
  • Quality Assurance: Provides input on compliance expectations and audit readiness.
  • Regulatory Affairs: Updates on submission status, approvals, and timelines.
See also  BA-BE Studies: SOP for Maintaining Investigator Site File (ISF) - V 2.0

4. Accountability

The Head of Clinical Operations is accountable for ensuring a formal pre-study kickoff meeting is conducted and documented for every BA/BE study prior to first subject screening.

5. Procedure

5.1 Meeting Planning and Scheduling

  1. Schedule the kickoff meeting at least 2 weeks before the planned first subject screening date.
  2. Circulate meeting invitation to all relevant stakeholders using Annexure-1: Kickoff Meeting Attendance List.
  3. Prepare agenda using Annexure-2: Pre-Study Kickoff Agenda Template.

5.2 Meeting Content

  1. The meeting must include discussion on the following:
    • Study objectives and overview
    • Study design (cross-over/parallel/fed/fasted)
    • Roles and responsibilities
    • Protocol highlights and critical procedures
    • Informed consent and EC submission status
    • Clinical supplies availability and randomization codes
    • Data management and CRF tracking
    • Adverse event reporting workflow
    • Quality assurance checks and audit timelines
    • Risk mitigation strategies
See also  BA-BE Studies: SOP for Handling Expired Reference Products - V 2.0

5.3 Documentation and Follow-Up

  1. Record meeting minutes in Annexure-3: Kickoff Meeting Minutes Log.
  2. Track open action items with responsible persons and deadlines in Annexure-4: Action Item Tracker.
  3. Distribute signed attendance sheet and meeting minutes to all participants.
  4. File documents in TMF and archive electronically.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRF: Case Report Form
  • TMF: Trial Master File
  • EC: Ethics Committee
  • CRO: Contract Research Organization

7. Documents

  1. Kickoff Meeting Attendance List – Annexure-1
  2. Pre-Study Kickoff Agenda Template – Annexure-2
  3. Kickoff Meeting Minutes Log – Annexure-3
  4. Action Item Tracker – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • CDSCO Guidance on Clinical Trial Management
  • Organization’s Clinical Study Management Policy
See also  BA-BE Studies: SOP for Protocol and SAP (Statistical Analysis Plan) Integration - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Kickoff Meeting Attendance List

Name Department Designation Email Signature
Rajesh Kumar Clinical Project Manager rajesh.k@domain.com

Annexure-2: Pre-Study Kickoff Agenda Template

Agenda Item Presenter Time Allocated
Study Overview & Objectives Meera Shah 10 min

Annexure-3: Kickoff Meeting Minutes Log

Date Meeting Summary Prepared By Reviewed By
16/04/2025 Study BE-040 team aligned on FPFV plan Sunita Reddy Dr. Arvind Shah

Annexure-4: Action Item Tracker

Action Item Owner Due Date Status
Submit EC approval letter to TMF Regulatory Affairs 18/04/2025 Pending

Revision History:

Revision Date Revision No. Details Reason Approved By
15/01/2022 1.0 Initial SOP New documentation QA Head
17/04/2025 2.0 Added annexures and clarified attendee responsibilities Operational standardization QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for Issuance of Raw Materials to Production – V 2.0
Next Post: Capsule: SOP for Reviewing Batch Manufacturing Records (BMRs) – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version